Bystolic Approved; Forest Prepares To Launch In Crowded Beta Blocker Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm hopes nebivolol's subgroup efficacy will set the novel beta blocker apart from others in its class.
You may also be interested in...
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.
Forest Vows To Double Pipeline Potential
Firm restates commitment to aclidinium for COPD.
Forest Vows To Double Pipeline Potential
Firm restates commitment to aclidinium for COPD.